# US 2023/0057428 A1 · Coronavirus disease (covid-19) vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057428 A1
- Document ID: US20230057428A1
- Status: Published application
- Kind: A1
- Application number: 17/817,708
- Filed: 2022-08-05
- Published: 2023-02-23
- Earliest claimed: 2020-03-06
- Assignees: Thomas Jefferson University
- Applicants: Thomas Jefferson University
- Inventors: Matthias Johannes SCHNELL; Christoph WIRBLICH; Drishya KURUP
- Web page: https://patentgrep.com/patent/US20230057428A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- C12N 2760/18443: viral genome or elements thereof as genetic vector
- C12N 2760/20042: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2760/20122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20143: viral genome or elements thereof as genetic vector
- C12N 2760/20243: viral genome or elements thereof as genetic vector
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.

## Claims

### Claim 1

An isolated nucleic acid encoding a recombinant virus comprising a SARS-CoV-2 spike protein (S) or a portion thereof, wherein the virus is a rabies virus, a vesicular stomatitis virus (VSV), or a measles virus, and wherein the portion of the SARS-CoV-2 spike protein (S) comprises a receptor binding site of the SARS-CoV-2 spike protein (S).

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated nucleic acid of claim 1, wherein the virus is a rhabdovirus.

### Claim 4 (depends on 1)

The isolated nucleic acid of claim 1, wherein the portion of the SARS-CoV-2 spike protein (S) is a S1 domain.

### Claim 5 (depends on 1)

The isolated nucleic acid of claim 1, wherein the nucleic acid comprises (a) a sequence encoding at least a portion of the genome of a measles virus and (b) a sequence encoding the SARS-CoV-2 spike protein (S) or the portion thereof.

### Claim 6 (depends on 5)

The isolated nucleic acid of claim 5, wherein the sequence encoding the SARS-CoV-2 spike protein (S) or portion thereof is inserted into positions 2, 3, or 6 of the genome of the measles virus.

### Claim 7 (depends on 1)

The isolated nucleic acid of claim 1, wherein the nucleic acid comprises (a) a sequence encoding at least a portion of the genome of a rabies virus and (b) a sequence encoding the SARS-CoV-2 spike protein (S) or the portion thereof.

### Claim 8 (depends on 7)

The isolated nucleic acid of claim 7, wherein the at least a portion of the genome of the rabies virus comprises an N gene and a P gene, and the sequence encoding the SARS-CoV-2 spike protein (S) or portion thereof is inserted into a position between the N gene and P gene.

### Claim 9 (depends on 1)

The isolated nucleic acid of claim 1, wherein the nucleic acid comprises (a) a sequence encoding at least a portion of the genome of a vesicular stomatitis virus (VSV), and (b) a sequence encoding the SARS-CoV-2 spike protein (S) or the portion thereof.

### Claim 10 (depends on 1)

The isolated nucleic acid of claim 1, wherein the protein comprising a SARS-CoV-2 spike protein (S) or a portion thereof is a fusion protein comprising a glycoprotein (G) or a portion thereof and the SARS-CoV-2 spike protein (S) or the portion thereof.

### Claim 11 (depends on 10)

The isolated nucleic acid of claim 10, wherein the fusion protein comprises a glycoprotein (G) or portion thereof fused to the 51 domain of a SARS-CoV-2 spike protein (S).

### Claim 12 (depends on 1)

The isolated nucleic acid of claim 1, wherein the nucleic acid comprises the sequence set forth in any one of SEQ ID NOs: 1-27.

### Claim 13 (depends on 12)

The isolated nucleic acid of claim 12, wherein the nucleic acid comprises the sequence set forth in SEQ ID NO: 2.

### Claim 14 (depends on 1)

The isolated nucleic acid of claim 1, wherein the SARS-CoV-2 spike protein (S) comprises the sequence of SEQ ID NO: 28; or a sequence comprising at least 98%, but not 100%, sequence identity to the sequence of SEQ ID NO: 28.

### Claim at position 15

15-21. (canceled)

### Claim 22 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 23 (depends on 1)

A vaccine comprising the isolated nucleic acid of claim 1, and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 23)

The vaccine of claim 23, further comprising an adjuvant.

### Claim 25 (depends on 24)

The vaccine of claim 24, wherein the adjuvant is MPLA 3D(6-acyl) in 2% squalene.

### Claim 26

(canceled)

### Claim 27 (depends on 23)

A method of generating an immune response against a SARS-CoV-2 virus in a subject in need thereof, the method comprising administering to the subject an effective amount of the vaccine of claim 23.

### Claim 28 (depends on 23)

A method of vaccinating a subject against a SARS-CoV-2 virus, the method comprising administering to the subject an effective amount of the vaccine of claim 23.

### Claim 29

(canceled)

### Claim 30 (depends on 23)

A method of treating and/or preventing a disease or disorder associated with a SARS-CoV-2 virus in a subject in need thereof, the method comprising administering to the subject an effective amount of the vaccine of claim 23.
